Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-310true0truetruetruetruetrue2024-01-01falseNo description of principal activity0truefalse 13266138 2024-01-01 2024-12-31 13266138 2023-01-01 2023-12-31 13266138 2024-12-31 13266138 2023-12-31 13266138 2023-01-01 13266138 c:Director1 2024-01-01 2024-12-31 13266138 c:Director2 2024-01-01 2024-12-31 13266138 d:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 13266138 d:PatentsTrademarksLicencesConcessionsSimilar 2023-12-31 13266138 d:CopyrightsPatentsTrademarksServiceOperatingRights 2024-01-01 2024-12-31 13266138 d:CurrentFinancialInstruments 2024-12-31 13266138 d:CurrentFinancialInstruments 2023-12-31 13266138 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 13266138 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 13266138 d:ShareCapital 2024-01-01 2024-12-31 13266138 d:ShareCapital 2024-12-31 13266138 d:ShareCapital 2023-01-01 2023-12-31 13266138 d:ShareCapital 2023-12-31 13266138 d:ShareCapital 2023-01-01 13266138 d:SharePremium 2024-01-01 2024-12-31 13266138 d:SharePremium 2024-12-31 13266138 d:SharePremium 2023-01-01 2023-12-31 13266138 d:SharePremium 2023-12-31 13266138 d:SharePremium 2023-01-01 13266138 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 13266138 d:RetainedEarningsAccumulatedLosses 2024-12-31 13266138 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 13266138 d:RetainedEarningsAccumulatedLosses 2023-12-31 13266138 d:RetainedEarningsAccumulatedLosses 2023-01-01 13266138 c:FRS102 2024-01-01 2024-12-31 13266138 c:Audited 2024-01-01 2024-12-31 13266138 c:FullAccounts 2024-01-01 2024-12-31 13266138 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13266138 c:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13266138 d:PatentsTrademarksLicencesConcessionsSimilar d:OwnedIntangibleAssets 2024-01-01 2024-12-31 13266138 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 13266138









ENNOGEN IP LTD









FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

 
ENNOGEN IP LTD
REGISTERED NUMBER: 13266138

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 3 
5,004,998
6,825,000

  
5,004,998
6,825,000

Current assets
  

Debtors: amounts falling due within one year
 4 
4,823,555
2,788,789

Cash at bank and in hand
 5 
247,772
4,845

  
5,071,327
2,793,634

Creditors: amounts falling due within one year
 6 
(642,193)
(928,266)

Net current assets
  
 
 
4,429,134
 
 
1,865,368

Total assets less current liabilities
  
9,434,132
8,690,368

  

Net assets
  
9,434,132
8,690,368


Capital and reserves
  

Called up share capital 
  
2,000
2,000

Share premium account
  
8,999,000
8,999,000

Profit and loss account
  
433,132
(310,632)

  
9,434,132
8,690,368


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 25 September 2025.




Gurdev Singh Ruprai
Jason Rodney Tate
Director
Director

Page 1

 
ENNOGEN IP LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024


Called up share capital
Share premium account
Profit and loss account
Total equity

£
£
£
£


At 1 January 2023
2,000
8,999,000
(46,378)
8,954,622


Comprehensive income for the year

Loss for the year

-
-
(264,254)
(264,254)


Other comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
(264,254)
(264,254)


Total transactions with owners
-
-
-
-



At 1 January 2024
2,000
8,999,000
(310,632)
8,690,368


Comprehensive income for the year

Profit for the year

-
-
743,764
743,764


Other comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
743,764
743,764


Total transactions with owners
-
-
-
-


At 31 December 2024
2,000
8,999,000
433,132
9,434,132


The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
ENNOGEN IP LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

The Company is a private company limited by shares, registered in the United Kingdom. The address of the registered office us Unit G4, Riverside Way, Dartford, Kent, DA1 5BS.
The principal activity of the Company during the year was that of the wholesale of pharmaceutical products.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of Section 26 Share-based Payment paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Ennogen Holdings Ltd as at 31 December 2024 and these financial statements may be obtained from Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS.

 
2.3

Going concern

These financial statements have been prepared on a going concern basis which assumes that the Company is able to realise its assets and discharge its liabilities in the normal course of business. At the reporting date the company has net assets of £9.4m (2023: £8.7m) and future projections show sufficient headroom to weather any future impacts of global uncertainties. 
The Directors consider it appropriate to prepare the financial statements on a going concern basis.

Page 3

 
ENNOGEN IP LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 The estimated useful lives range as follows:

Patents, trademarks and licences
-
Straight line over 5 years

Page 4

 
ENNOGEN IP LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Intangible assets




Patents, trademarks and licences

£



Cost


At 1 January 2024
9,100,000



At 31 December 2024

9,100,000



Amortisation


At 1 January 2024
2,275,000


Charge for the year on owned assets
1,820,002



At 31 December 2024

4,095,002



Net book value



At 31 December 2024
5,004,998



At 31 December 2023
6,825,000



Page 5

 
ENNOGEN IP LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


Debtors

2024
2023
£
£


Amounts owed by group undertakings
4,815,485
2,788,789

Other debtors
8,070
-

4,823,555
2,788,789


Amounts owed to group undertakings are unsecured, interest free and payable on demand.


5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
247,772
4,845

247,772
4,845



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
19,238
1,032

Corporation tax
615,155
478,867

Other taxation and social security
-
430,283

Accruals and deferred income
7,800
18,084

642,193
928,266


Amounts owed to group undertakings are unsecured, interest free and payable on demand.


7.


Controlling party

The immediate parent undertaking is Ennogen Investments Limited, a company incorporated in England & Wales.
The Company's ultimate parent undertaking is Ennogen Holdings Limited, a company incorporated in England & Wales and this is the smallest and largest Group for which consolidated financial statements are prepared. Copies of these financial statements are available from the Company's registered office as noted in the Company Information.
The ultimate controlling party is Mr G S Ruprai.

Page 6

 
ENNOGEN IP LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 25 September 2025 by John Daly (Senior Statutory Auditor) on behalf of Forvis Mazars LLP.

Page 7